Experimental benefits of sex hormones on vascular function and the outcome of hormone therapy in cardiovascular disease

Current Cardiology Reviews

Volumn 4, Issue 4, 2008, Pages 309-322

  Ross, Reagan L ^a   Serock, Michelle R ^a   Khalil, Raouf A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Calcium; Coronary artery disease; Endothelium; Estrogen; Hypertension; Nitric oxide; Progesterone; Testosterone; Vascular smooth muscle

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ALPHA ZEARALENOL; BIOCHANIN A; CELERIN; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; COUMESTROL; DAIDZEIN; DIETHYLSTILBESTROL; EQUOL; ESTRADIOL; ESTRADIOL BENZOATE; ESTRADIOL CIPIONATE; ESTRADIOL VALERATE; ESTRIOL; ESTROGEN; ESTRONE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GENISTEIN; IDOXIFENE; MESTRANOL; PLACEBO; PREMPAC; RALOXIFENE; RESVERATROL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZEARALENONE;

ANTIINFLAMMATORY ACTIVITY; BLOOD VESSEL FUNCTION; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; GENETIC POLYMORPHISM; HEART INFARCTION; HORMONAL THERAPY; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MENOPAUSAL SYNDROME; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 65649154490     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340308786349462     Document Type: Review

References (116)

1. Orshal JM, Khalil RA. Gender, sex hormones, and vascular tone. Am J Physiol Regul Integr Comp Physiol 2004; 286(2): R233-49.
2. Reckelhoff JF. Sex steroids, cardiovascular disease, and hypertension: unanswered questions and some speculations. Hypertension 2005; 45(2): 170-4.
3. Mendelsohn ME. Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol 2002; 90(1A): 3F-6F.
4. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005; 308(5728): 1583-7.
5. Jazbutyte V, Arias-Loza PA, Hu K, et al. Ligand-dependent activation of ERbeta lowers blood pressure and attenuates cardiac hypertrophy in ovariectomized spontaneously hypertensive rats. Cardiovasc Res 2008; 77(4): 774-81.
6. Rosano GM, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 1993; 342(8864): 133-6.
7. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335(7): 453-61.
8. Dubey RK, Imthurn B, Zacharia LC, Jackson EK. Hormone replacement therapy and cardiovascular disease: what went wrong and where do we go from here? Hypertension 2004; 44(6): 789-95.
9. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280(7): 605-13.
10. Grady D, Herrington D, Bittner V, et al. HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288(1): 49-57.
11. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288(3): 321-33.
12. Grimes DA, Lobo RA. Perspectives on the Women's Health Initiative trial of hormone replacement therapy. Obstet Gynecol 2002; 100(6): 1344-53.
13. Koledova VV, Khalil RA. Sex hormone replacement therapy and modulation of vascular function in cardiovascular disease. Expert Rev Cardiovasc Ther 2007; 5(4): 777-89.
14. Vitale C, Fini M, Leonardo F, et al. Effect of estradiol valerate alone or in association with cyproterone acetate upon vascular function of postmenopausal women at increased risk for cardiovascular disease. Maturitas 2001; 40(3): 239-45.
15. Seeger H, Petersen G, Schulte-Wintrop E, Teichmann AT, Mueck AO. Effect of two oral contraceptives containing ethinylestradiol and levonorgestrel on serum and urinary surrogate markers of endothelial function. Int J Clin Pharmacol Ther 2002; 40(4): 150-7.
16. Johnson JV, Lowell J, Badger GJ, Rosing J, Tchaikovski S, Cushman M. Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. Obstet Gynecol 2008; 111(2 Pt 1): 278-84.
17. Register TC, Adams MR, Golden DL, Clarkson TB. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol 1998; 18(7): 1164-71.
18. Head KA. Estriol: safety and efficacy. Altern Med Rev 1998; 3(2):101-13.
19. Dubey RK, Jackson EK, Gillespie DG, Zacharia LC, Imthurn B, Keller PJ. Clinically used estrogens differentially inhibit human aortic smooth muscle cell growth and mitogen-activated protein kinase activity. Arterioscler Thromb Vasc Biol 2000; 20(4): 964-72.
20. Vera R, Jiménez R, Lodi F, et al. Genistein restores caveolin-1 and AT-1 receptor expression and vascular function in large vessels of ovariectomized hypertensive rats. Menopause 2007; 14(5): 933-40.
21. Si H, Liu D. Genistein, a soy phytoestrogen, upregulates the expression of human endothelial nitric oxide synthase and lowers blood pressure in spontaneously hypertensive rats. J Nutr 2008; 138(2): 297-304.
22. Sanada M, Higashi Y, Nakagawa K, et al. A comparison of low-dose and standard-dose oral estrogen on forearm endothelial function in early postmenopausal women. J Clin Endocrinol Metab 2003; 88(3): 1303-9.
23. Wakatsuki A, Ikenoue N, Shinohara K, Watanabe K, Fukaya T. Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women. Arterioscler Thromb Vasc Biol 2004; 24(3): 571-6.
24. Mueck AO, Genazzani AR, Samsioe G, Vukovic-Wysocki I, Seeger H. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application. Menopause 2007; 14(6): 978-84.
25. Ho JY, Chen MJ, Sheu WH, et al. Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women. Hum Reprod 2006; 21(10): 2715-20.
26. Sumino H, Ichikawa S, Kasama S, et al. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. Atherosclerosis 2006; 189(2): 436-42.
27. Haas E, Meyer MR, Schurr U, et al. Differential effects of 17beta-estradiol on function and expression of estrogen receptor alpha, estrogen receptor beta, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension 2007; 49(6): 1358-63.
28. Zhu Y, Bian Z, Lu P, et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor β. Science 2002; 295(5554): 505-508.
29. Figtree GA, McDonald D, Watkins H, Channon KM. Truncated estrogen receptor alpha 46-kDa isoform in human endothelial cells: relationship to acute activation of nitric oxide synthase. Circulation 2003; 107(1): 120-6.
30. Flouriot G, Griffin C, Kenealy M, Sonntag-Buck V, Gannon F. Differentially expressed messenger RNA isoforms of the human estrogen receptor-alpha gene are generated by alternative splicing and promoter usage. Mol Endocrinol 1998; 12(12): 1939-54.
31. Hayashi K, Maeda S, Iemitsu M, et al. Differences in the relationship between estrogen receptor alpha gene polymorphisms and arterial stiffness in older humans. Am J Hypertens 2007; 20(6): 650-6.
32. Hisamoto K, Bender JR. Vascular cell signaling by membrane estrogen receptors. Steroids 2005; 70(5-7): 382-7.
33. Leung SW, Teoh H, Keung W, Man RY. Non-genomic vascular actions of female sex hormones: physiological implications and signalling pathways. Clin Exp Pharmacol Physiol 2007; 34(8): 822-6.
34. Wynne FL, Payne JA, Cain AE, Reckelhoff JF, Khalil RA. Agerelated reduction in estrogen receptor-mediated mechanisms of vascular relaxation in female spontaneously hypertensive rats. Hypertension 2004; 43(2): 405-12.
35. Post WS, Goldschmidt-Clermont PJ, Wilhide CC, et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res 1999; 43(4): 985-91.
36. Bolego C, Vegeto E, Pinna C, Maggi A, Cignarella A. Selective agonists of estrogen receptor isoforms: new perspectives for cardiovascular disease. Arterioscler Thromb Vasc Biol 2006; 26(10): 2192-9.
37. Tsang SY, Yao X, Chan FL, et al. Estrogen and tamoxifen modulate cerebrovascular tone in ovariectomized female rats. Hypertension 2004; 44(1): 78-82.
38. Sun J, Huang YR, Harrington WR, Sheng S, Katzenellenbogen JA, Katzenellenbogen BS. Antagonists selective for estrogen receptor alpha. Endocrinology 2002; 143(3): 941-7.
39. Pinna C, Bolego C, Sanvito P, et al. Raloxifene elicits combined rapid vasorelaxation and long-term anti-inflammatory actions in rat aorta. J Pharmacol Exp Ther 2006; 319(3): 1444-51.
40. Mosca L, Barrett-Connor E, Wenger NK, et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol 2001; 88(4): 392-5.
41. Barrett-Connor E, Mosca L, Collins P, et al. Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006 13; 355(2): 125-37.
42. Harrington WR, Sheng S, Barnett DH, Petz LN, Katzenellenbogen JA, Katzenellenbogen BS. Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol Cell Endocrinol 2003; 206(1-2): 13-22.
43. Sun J, Meyers MJ, Fink BE, Rajendran R, Katzenellenbogen JA, Katzenellenbogen BS. Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Endocrinology 1999; 140(2): 800-4.
44. Seely EW, Brosnihan KB, Jeunemaitre X, et al. Effects of conjugated oestrogen and droloxifene on the renin-angiotensin system, blood pressure and renal blood flow in postmenopausal women. Clin Endocrinol (Oxf) 2004; 60(3): 315-21.
45. Xu YY, Yang C, Li SN. Effects of genistein on angiotensin-converting enzyme in rats. Life Sci 2006; 79(9): 828-37.
46. Dean SA, Tan J, O'Brien ER, Leenen FH. 17beta-estradiol down-regulates tissue angiotensin-converting enzyme and ANG II type 1 receptor in female rats. Am J Physiol Regul Integr Comp Physiol 2005; 288(3): R759-66.
47. Dubey RK, Gillespie DG, Imthurn B, Rosselli M, Jackson EK, Keller PJ. Phytoestrogens inhibit growth and MAP kinase activity in human aortic smooth muscle cells. Hypertension 1999; 33(1 Pt 2): 177-82.
48. Barchiesi F, Jackson EK, Gillespie DG, Zacharia LC, Fingerle J, Dubey RK. Methoxyestradiols mediate estradiol-induced antimitogenesis in human aortic SMCs. Hypertension 2002; 39(4): 874-9.
49. 2+ entry mechanisms of coronary vasoconstriction. Arterioscler Thromb Vasc Biol 1999; 19(4): 1034-40.
50. Kauser K, Rubanyi GM. Gender difference in endothelial dysfunction in the aorta of spontaneously hypertensive rats. Hypertension 1995; 25(4 Pt 1): 517-23.
51. Rubanyi GM, Freay AD, Kauser K, et al. Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta. Gender difference and effect of estrogen receptor gene disruption. J Clin Invest 1997; 99(10): 2429-37.
52. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999; 103(3): 401-6. Erratum in: J Clin Invest 1999; 103(9): 1363.
53. Pare G, Krust A, Karas RH, et al. Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res 2002; 90(10): 1087-92.
54. Darblade B, Pendaries C, Krust A, et al. Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, estrogen receptor. Circ Res 2002; 90(4): 413-9.
55. Nilsson BO, Ekblad E, Heine T, Gustafsson JA. Increased magnitude of relaxation to oestrogen in aorta from oestrogen receptor beta knock-out mice. J Endocrinol 2000; 166(2): R5-9.
56. Widder J, Pelzer T, von Poser-Klein C, et al. Improvement of endothelial dysfunction by selective estrogen receptor-alpha stimulation in ovariectomized SHR. Hypertension 2003; 42(5): 991-6.
57. Chambliss KL, Shaul PW. Estrogen modulation of endothelial nitric oxide synthase. Endocr Rev 2002; 23(5): 665
58. Chambliss KL, Yuhanna IS, Anderson RG, Mendelsohn ME, Shaul PW. ERbeta has nongenomic action in caveolae. Mol Endocrinol 2002; 16(5): 938-46.
59. Forte P, Kneale BJ, Milne E, et al. Evidence for a difference in nitric oxide biosynthesis between healthy women and men. Hypertension 1998; 32(4): 730-4.
60. 2+-independent activation of endothelial nitric-oxide synthase/Hsp90 involving ERK1/2 and Akt phosphorylation in human endothelial cells. J Biol Chem 2006; 281(37): 27335-45.
61. Haynes MP, Sinha D, Russell KS, et al. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res 2000; 87(8): 677-82.
62. Hernández I, Delgado JL, Díaz J, et al. 17beta-estradiol prevents oxidative stress and decreases blood pressure in ovariectomized rats. Am J Physiol Regul Integr Comp Physiol 2000; 279(5): R1599-605.
63. Barber DA, Miller VM. Gender differences in endothelium-dependent relaxations do not involve NO in porcine coronary arteries. Am J Physiol 1997; 273(5 Pt 2): H2325-32.
64. Egan KM, Lawson JA, Fries S, et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004; 306(5703): 1954-7.
65. Bilsel AS, Moini H, Tetik E, Aksungar F, Kaynak B, Ozer A. 17Beta-estradiol modulates endothelin-1 expression and release in human endothelial cells. Cardiovasc Res 2000; 46(3): 579-84.
66. Dubey RK, Jackson EK, Keller PJ, Imthurn B, Rosselli M. Estradiol metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. Hypertension 2001; 37(2 Part 2): 640-4.
67. David FL, Carvalho MH, Cobra AL, et al. Ovarian hormones modulate endothelin-1 vascular reactivity and mRNA expression in DOCA-salt hypertensive rats. Hypertension 2001; 38(3 Pt 2): 692-6.
68. Collins P, Rosano GM, Sarrel PM, et al. 17 beta-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995; 92(1): 24-30.
69. Nickenig G, Strehlow K, Wassmann S, et al. Differential effects of estrogen and progesterone on AT(1) receptor gene expression in vascular smooth muscle cells. Circulation 2000; 102(15): 1828-33.
70. Salamanca DA, Khalil RA. Protein kinase C isoforms as specific targets for modulation of vascular smooth muscle function in Hypertension Biochem Pharmacol 2005; 70(11): 1537-47.
71. i in vascular smooth muscle cells of female rat. Am J Physiol Cell Physiol 2000; 278(4): C834-44.
72. i during inhibition of coronary smooth muscle contraction by 17beta-estradiol, progesterone, and testosterone. J Pharmacol Exp Ther 1999; 291(1): 44-52.
73. Han G, Yu X, Lu L, et al. Estrogen receptor alpha mediates acute potassium channel stimulation in human coronary artery smooth muscle cells. J Pharmacol Exp Ther 2006; 316(3): 1025-30.
74. 2+ efflux from female porcine coronary arterial smooth muscle. Am J Physiol 1999; 276(3 Pt 2): H926-34.
75. Kanashiro CA, Khalil RA. Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle. Am J Physiol Cell Physiol 2001; 280(1): C34-45.
76. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol 2000; 522(Pt 2): 177-85.
77. Lee DL, Webb RC, Jin L. Hypertension and RhoA/Rho-kinase signaling in the vasculature: highlights from the recent literature. Hypertension 2004; 44(6): 796-9.
78. Noma K, Oyama N, Liao JK. Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol 2006; 290(3): C661-8.
79. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25(9): 1767-75.
80. Chrissobolis S, Budzyn K, Marley PD, Sobey CG. Evidence that estrogen suppresses rho-kinase function in the cerebral circulation in vivo. Stroke 2004; 35(9): 2200-5.
81. Simoncini T, Scorticati C, Mannella P, et al. Estrogen receptor alpha interacts with Galpha13 to drive actin remodeling and endothelial cell migration via the RhoA/Rho kinase/moesin pathway. Mol Endocrinol 2006; 20(8): 1756-71.
82. Groten T, Pierce AA, Huen AC, Schnaper HW. 17 beta-estradiol transiently disrupts adherens junctions in endothelial cells. FASEB J 2005; 19(10): 1368-70.
83. Felty Q, Roy D. Estrogen, mitochondria, and growth of cancer and non-cancer cells. J Carcinog 2005; 4(1): 1.
84. Cid MC, Esparza J, Schnaper HW, et al. Estradiol enhances endothelial cell interactions with extracellular matrix proteins via an increase in integrin expression and function. Angiogenesis 1999; 3(3): 271-80.
85. Wingrove CS, Garr E, Godsland IF, Stevenson JC. 17beta-oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim Biophys Acta 1998; 1406(2): 169-74.
86. Sumino H, Ichikawa S, Kasama S, et al. Effect of transdermal hormone replacement therapy on carotid artery wall thickness and levels of vascular inflammatory markers in postmenopausal women. Hypertens Res 2005; 28(7): 579-84.
87. Gao H, Liang M, Bergdahl A, et al. Estrogen attenuates vascular expression of inflammation associated genes and adhesion of monocytes to endothelial cells. Inflamm Res 2006; 55(8): 349-53.
88. Geraldes P, Gagnon S, Hadjadj S, et al. Estradiol blocks the induction of CD40 and CD40L expression on endothelial cells and prevents neutrophil adhesion: an ERalpha-mediated pathway. Cardiovasc Res 2006; 71(3): 566-73.
89. Xing D, Feng W, Miller AP, et al. Estrogen modulates TNF-alpha-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-beta activation. Am J Physiol Heart Circ Physiol 2007; 292(6): H2607-12.
90. Arenas IA, Armstrong SJ, Xu Y, Davidge ST. Tumor necrosis factor-alpha and vascular angiotensin II in estrogen-deficient rats. Hypertension 2006; 48(3): 497-503.
91. Brandes RP, Fleming I, Busse R. Endothelial aging. Cardiovasc Res 2005; 66(2): 286-94.
92. Duckles SP, Krause DN, Stirone C, Procaccio V. Estrogen and mitochondria: a new paradigm for vascular protection? Mol Interv 2006; 6(1): 26-35.
93. Yeboah J, Reboussin DM, Waters D, Kowalchuk G, Herrington DM. Effects of estrogen replacement with and without medroxyprogesterone acetate on brachial flow-mediated vasodilator responses in postmenopausal women with coronary artery disease. Am Heart J 2000; 153(3): 439-44.
94. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002; 53(3): 605-19.
95. López-Jaramillo P, Díaz LA, Pardo A, Parra G, Jaimes H, Chaudhuri G. Estrogen therapy increases plasma concentrations of nitric oxide metabolites in postmenopausal women but increases flow-mediated vasodilation only in younger women. Fertil Steril 2004; 82(6): 1550-5.
96. Sherwood A, Bower JK, McFetridge-Durdle J, Blumenthal JA, Newby LK, Hinderliter AL. Age moderates the short-term effects of transdermal 17beta-estradiol on endothelium-dependent vascular function in postmenopausal women. Arterioscler Thromb Vasc Biol 2007; 27(8): 1782-7.
97. Naftolin F, Taylor HS, Karas R, et al. Women's Health Initiative. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 2004; 81(6): 1498-501.
98. Hsia J, Langer RD, Manson JE, et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006; 166(3): 357-65.
99. Harman SM, Brinton EA, Cedars M, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005; 8(1): 3-12.
100. Kelemen M, Vaidya D, Waters DD, et al. Hormone therapy and antioxidant vitamins do not improve endothelial vasodilator function in postmenopausal women with established coronary artery disease: a substudy of the Women's Angiographic Vitamin and Estrogen (WAVE) trial. Atherosclerosis 2005; 179(1): 193-200.
101. Chataigneau T, Zerr M, Chataigneau M, et al. Chronic treatment with progesterone but not medroxyprogesterone acetate restores the endothelial control of vascular tone in the mesenteric artery of ovariectomized rats. Menopause 2004; 11(3): 255-63.
102. Minshall RD, Pavcnik D, Browne DL, Hermsmeyer K. Nongenomic vasodilator action of progesterone on primate coronary arteries. J Appl Physiol 2002; 92(2): 701-8.
103. Wassmann K, Wassmann S, Nickenig G. Progesterone antagonizes the vasoprotective effect of estrogen on antioxidant enzyme expression and function. Circ Res 2005; 97(10): 1046-54.
104. Sunday L, Tran MM, Krause DN, Duckles SP. Estrogen and progestagens differentially modulate vascular proinflammatory factors. Am J Physiol Endocrinol Metab 2006; 291(2): E261-7.
105. Faludi AA, Aldrighi JM, Bertolami MC, et al. Progesterone abolishes estrogen and/or atorvastatin endothelium dependent vasodilatory effects. Atherosclerosis 2004; 177(1): 89-96.
106. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17(1): 217-21.
107. Wynne FL, Khalil RA. Testosterone and coronary vascular tone: implications in coronary artery disease. J Endocrinol Invest 2003; 26(2): 181-6.
108. Montalcini T, Gorgone G, Gazzaruso C, Sesti G, Perticone F, Pujia A. Endogenous testosterone and endothelial function in postmenopausal women. Coron Artery Dis 2007; 18(1): 9-13.
109. Ding AQ, Stallone JN. Testosterone-induced relaxation of rat aorta is androgen structure specific and involves K+ channel activation. J Appl Physiol 2001; 91(6): 2742-50.
110. Honda H, Unemoto T, Kogo H. Different mechanisms for testosterone-induced relaxation of aorta between normotensive and spontaneously hypertensive rats. Hypertension 1999; 34(6): 1232-6.
111. Norata GD, Tibolla G, Seccomandi PM, Poletti A, Catapano AL. Dihydrotestosterone decreases tumor necrosis factor-alpha and lipopolysaccharide-induced inflammatory response in human endothelial cells. J Clin Endocrinol Metab 2006; 91(2): 546-54.
112. Song D, Arikawa E, Galipeau D, Battell M, McNeill JH. Androgens are necessary for the development of fructose-induced Hypertension Hypertension 2004; 43(3): 667-72.
113. Zhai P, Eurell TE, Cooke PS, Lubahn DB, Gross DR. Myocardial ischemia-reperfusion injury in estrogen receptor-alpha knockout and wild-type mice. Am J Physiol Heart Circ Physiol 2000; 278(5): H1640-7.
114. Wang M, Crisostomo P, Wairiuko GM, Meldrum DR. Estrogen receptor-alpha mediates acute myocardial protection in females. Am J Physiol Heart Circ Physiol 2006; 290(6): H2204-9.
115. Hinojosa-Laborde C, Craig T, Zheng W, Ji H, Haywood JR, Sandberg K. Ovariectomy augments hypertension in aging female Dahl salt-sensitive rats. Hypertension 2004; 44(4): 405-9.
116. 2+ entry mechanisms of vasoconstriction in Wistar-Kyoto and spontaneously hypertensive rats. Hypertension 1999; 34(4 Pt 2): 931-6.